Resonetics announced today that it has signed an agreement to acquire Resolution Medical, a leading provider of integrated design and manufacturing solutions for complex medical devices. Resolution Medical is headquartered in Fridley, MN, with additional operations in the Netherlands, and is currently owned by Arcline Investment Management..

Resonetics 今日宣布已签署协议，将收购复杂医疗器械集成设计与制造解决方案的领先提供商 Resolution Medical。Resolution Medical 总部位于明尼苏达州弗里德利，在荷兰设有其他业务，目前由 Arcline Investment Management 拥有。

The transaction adds complementary capabilities in high-growth therapeutic markets, including neuromodulation, structural heart, and interventional cardiology to current Resonetics offerings. The acquisition is expected to close in 2026, pending regulatory approvals and customary closing conditions..

该交易为Resonetics当前的业务增加了在高增长治疗市场中的互补能力，包括神经调节、结构性心脏病和介入心脏病学。此次收购预计将在2026年完成，但需等待监管机构的批准和惯例的交割条件。

'Resolution Medical is an exceptional organization with deep technical expertise, a strong innovation culture, and a proven track record in designing and developing complex medical devices for the most innovative companies,' said Kevin Kelly, CEO of Resonetics. 'This acquisition will enhance our ability to deliver fully integrated solutions for customers in high-growth markets like neuromodulation and structural heart and supports our vision of becoming the most comprehensive partner in the medical device industry.'.

“Resolution Medical 是一家卓越的组织，拥有深厚的技术专长、强大的创新文化，以及为最具创新性的公司设计和开发复杂医疗设备的成功记录，”Resonetics 首席执行官凯文·凯利表示。“此次收购将增强我们为神经调节和结构性心脏病等高增长市场客户提供完全集成解决方案的能力，并支持我们成为医疗器械行业最全面合作伙伴的愿景。”

'This acquisition represents the ideal outcome for our customers and for our employees. Our customers will benefit from access to deeper capabilities and a more integrated, expansive partner,' said Peter Herman, CEO of Resolution Medical. 'By joining Resonetics, our employees also gain access to the skills, resources, and opportunities of a larger organization.

“此次收购对我们的客户和员工来说都是最理想的结果。我们的客户将受益于更深入的能力以及更紧密、更广泛的合作伙伴关系，”Resolution Medical首席执行官彼得·赫尔曼表示。“通过加入Resonetics，我们的员工还将获得更大组织的技能、资源和机会。”

Resolution Medical will be able to operate at greater scale and deliver enhanced solutions to our customers while continuing to support their programs with the same teams, expertise, and commitment they rely on today.'.

Resolution Medical 将能够扩大规模运营，并为我们的客户提供更优质的解决方案，同时继续以客户今天所依赖的相同团队、专业知识和承诺支持他们的项目。

Resolution Medical brings more than 240 employees, including over 100 engineers, and a strong reputation for delivering high-quality design engineering, new product introduction (NPI), and cleanroom production capabilities. The company supports a wide range of Class II and III devices and has built deep customer relationships, particularly in the neuromodulation and structural heart markets..

Resolution Medical拥有240多名员工，其中包括100多名工程师，凭借高质量的设计工程、新产品导入（NPI）以及洁净室生产能力而享有盛誉。该公司支持各种各样的II类和III类设备，并与客户建立了深厚的关系，尤其是在神经调节和结构性心脏病市场。

Backed by funds managed by global investment firm Carlyle and leading private equity firm GTCR, Resonetics provides end-to-end product development and manufacturing services, from prototyping through high-volume production. The addition of Resolution Medical enhances Resonetics' ability to support customers with increasingly complex devices across the full product lifecycle..

在全球投资公司凯雷（Carlyle）和领先的私募股权公司GTCR管理的基金支持下，Resonetics提供从原型设计到大规模生产的端到端产品开发和制造服务。收购Resolution Medical增强了Resonetics在产品全生命周期中支持客户应对日益复杂设备的能力。

Until the transaction closes, Resonetics and Resolution Medical will continue to operate independently. Nelson Mullins Riley & Scarborough acted as legal advisor to Resonetics.

在交易完成之前，Resonetics 和 Resolution Medical 将继续独立运营。Nelson Mullins Riley & Scarborough 担任 Resonetics 的法律顾问。

About Resonetics

关于Resonetics

Founded in 1987, Resonetics is a pioneer in advanced engineering and manufacturing solutions for the medical device industry. Resonetics is a leader in laser processing, nitinol manufacturing, thin-wall stainless steel, nitinol & precious metal tubing, and photochemical machining. With strategically located LightSpeed Labs® and AGILE Product Development® centers, Resonetics is committed to quality, speed, innovation, and a great customer experience.

成立于1987年，Resonetics 是医疗设备行业先进工程和制造解决方案的先驱。Resonetics 是激光加工、镍钛诺制造、薄壁不锈钢、镍钛诺和贵金属管材以及光化学蚀刻领域的领导者。通过战略性布局的 LightSpeed Labs® 和 AGILE 产品开发® 中心，Resonetics 致力于提供高质量、快速度、创新性以及卓越的客户体验。

The company is ISO 13485:2016 certified with 18 facilities and more than 3,000 associates in the United States, Canada, Costa Rica, Israel, and Switzerland. Resonetics is backed by leading private equity firms Carlyle and GTCR. Learn more at www.resonetics.com..

该公司通过了ISO 13485:2016认证，在美国、加拿大、哥斯达黎加、以色列和瑞士拥有18个设施和3000多名员工。Resonetics得到了领先的私募股权公司凯雷集团（Carlyle）和GTCR的支持。欲了解更多信息，请访问www.resonetics.com。

About GTCR

关于GTCR

Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors.

成立于1980年的GTCR是一家领先的私募股权公司，专注于“The Leaders Strategy™”投资策略——在核心领域寻找并与管理领导者合作，通过有机增长和战略性收购来识别、获取并打造市场领先的企业。GTCR专注于在商业与消费者服务、金融服务与技术、医疗保健以及技术、媒体和电信行业投资于具有变革性增长的公司。

Since its inception, GTCR has invested more than $30 billion in approximately 300 companies, and the firm currently manages approximately $50 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn..

自成立以来，GTCR 已在约 300 家公司投资超过 300 亿美元，目前该机构管理着约 500 亿美元的股权资本。GTCR 总部位于芝加哥，在纽约和西棕榈滩设有办事处。欲了解更多信息，请访问 www.gtcr.com。请在 LinkedIn 上关注我们。

About Carlyle

关于卡莱尔

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and operates through three segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $474 billion of assets under management as of September 30, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest.

凯雷集团（纳斯达克代码：CG）是一家全球投资公司，拥有深厚的行业专业知识，跨其业务部署私人资本，并通过三个部门运营：全球私募股权、全球信贷和凯雷AlpInvest。截至2025年9月30日，凯雷管理的资产规模达4740亿美元，其宗旨是为投资者、投资组合公司以及我们生活和投资的社区明智投资并创造价值。

Carlyle employs more than 2,400 people in 27 offices across four continents. Further information is available at carlyle.com. Follow Carlyle on LinkedIn at The Carlyle Group and on X at @OneCarlyle..

卡莱尔在四大洲的27个办事处拥有超过2400名员工。更多信息可访问carlyle.com。在LinkedIn上关注卡莱尔The Carlyle Group，或在X上关注@OneCarlyle。

Source: prnewswire.com

来源：prnewswire.com